MSI Methylation Sciences raises $39.6 mln to treat depression
Vancouver-based clinical-stage pharmaceutical company MSI Methylation Sciences Inc has secured about $39.6 million (US$30 million) in funding. The investor was Quark Venture, a Canadian life sciences venture capital firm. MSI is developing an oral, small-molecule therapy for adjunctive treatment of major depressive disorder. The funds raised from Quark will facilitate further product development in a phase 2 B trial. Founded in 2007, MSI is led by President Nancy Harrison, formerly a partner at Ventures West Management. The company is also backed by British venture capital firm Inventages Venture Capital.
7 October 2016•4 mins read
